PCM
TBIO

Prelude Capital Management’s Translate Bio, Inc. Common Stock TBIO Stock Holding History

Prelude Capital Management’s Portfolio TBIO Stock Details TBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-1,700
Closed -$30K – 2562
2020
Q2 		$30K Buy
+1,700
New +$25.6K ﹤0.01% 1297

Other funds holding TBIO

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
AVA
Atlas Venture Advisors Boston, Massachusetts $143M AUM 25.68% 1-Year Est. Return
FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Prelude Capital Management's TBIO Position: Q4 2020 in Review

Prelude Capital Management sold out of Translate Bio, Inc. Common Stock (TBIO) in Q4 2020, closing a stake of 400 shares — an estimated $5K sold.

Prelude Capital Management first reported a position in TBIO in Q2 2019 and held it in 4 quarters. The position peaked at $13K in Q4 2019. 150 funds tracked by Wall St. Rank hold TBIO as of Q4 2020.

  • Prelude Capital Management reported no remaining Translate Bio, Inc. Common Stock position as of Q4 2020 after selling out during the quarter.
  • Prelude Capital Management sold 400 Translate Bio, Inc. Common Stock shares in Q4 2020, an estimated $5K.
  • Prelude Capital Management first reported a position in Translate Bio, Inc. Common Stock in Q2 2019 and held it in 4 quarters.
  • Prelude Capital Management's Translate Bio, Inc. Common Stock position peaked at $13K in Q4 2019.
  • 150 funds tracked by Wall St. Rank held Translate Bio, Inc. Common Stock as of Q4 2020.

Based on Prelude Capital Management's 13F filing for Q4 2020, filed 16 Feb 2021.